Navigation Links
Amarantus BioScience Launches New Website
Date:1/28/2013

SUNNYVALE, Calif., Jan. 28, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with the neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, today announced the launch of the Company's new website at www.amarantus.com

"2012 was an exceptionally productive year for Amarantus with the acquisition of two diagnostic platforms to expand our pipeline, the addition of several industry experts to our advisory boards, and positive efficacy data in our Traumatic Brain Injury program," said Gerald Commissiong , President and CEO.  "We started 2013 demonstrating positive efficacy data for MANF in our Parkinson's program, and expect to make additional progress early this year with our diagnostic programs for chronic illnesses such as Parkinson's and Alzheimer's diseases."

To sign up for email alerts, click on the following link: http://www.amarantus.com/email-alerts.

About Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF)

MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein that corrects protein misfolding, one of the major causes of apoptosis (Programmed Cell Death). Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) is believed to have broad potential because it is a naturally-occurring protein produced by the body for the purpose of reducing and preventing apoptosis (in response to injury or disease), via the unfolded protein response. By manufacturing MANF and administering it to the body, Amarantus is seeking to use a regenerative medicine approach to assist the body with higher quantities of MANF when needed.  Amarantus is the front-runner and primary holder of intellectual property (IP) around MANF, and is initially focusing on the development of MANF-based protein therapeutics.  MANF's current lead indication is Parkinson's disease with additional focus on Traumatic Brain Injury (TBI.  Future indications may include myocardial infarction and certain rare and ultra-rare orphan diseases where MANF is currently being evaluated.  

The Company also owns an inventory of 88 cell lines referred to as "PhenoGuard Cell Lines." MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line, and it is anticipated that additional therapeutic proteins useful for various therapeutic approaches to the Central Nervous System will be identified from the Company's inventory of PhenoGuard Cell Lines.

About Amarantus BioScience, Inc.

Amarantus BioScience, Inc. is a development-stage biotechnology company founded in January 2008.  The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases.  The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit www.Amarantus.com. To follow the Company, please sign-up for email alerts, and follow the Company on Twitter and Facebook.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

MEDIA CONTACTS

Amarantus Bioscience, Inc.
(408) 737-2734 x109
pr@amarantus.com

Investor/Media Contact:
IR Sense, LLC
Remy Bernarda
415-203-6386
remy@irsense.com 


'/>"/>
SOURCE Amarantus BioScience, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Amarantus Bioscience Launches Online Corporate Communication Channels
2. Amarantus Bioscience to Present at OneMedForum 2013
3. Amarantus Appoints Super Bowl Champion Toi Cook to Board of Advisors to Advance TBI Program
4. Amarantus Completes Name Change and CUSIP Change
5. Amarantus BioSciences Announces Positive Data for MANF in Delivery Diffusion Animal Model of Parkinsons Disease
6. Amarantus BioSciences Demands Cessation of Unauthorized Listing on Berlin-Bremen Stock Exchange
7. OneMedPlace Releases Update to Research Report on Amarantus Biosciences Focused on New Positive Ischemic Heart Disease Efficacy Data for MANF in Animals
8. Amarantus BioSciences Wins MANF Patent Challenge in Europe
9. Amarantus BioSciences Issues CEO Letter to Shareholders
10. Amarantus BioSciences Secures $1.1 Million in Financing
11. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... ... a redesigned, easier-to-navigate website for all six of their healthcare job boards. ... dentists, pharmacists, physical and occupational therapists, and biotechnicians, DocCafe.com and the MedJobCafe.com ...
(Date:6/22/2017)... ... June 21, 2017 , ... RMC ... Carolina, and engages Timothy Reinhardt to manage the new site. , Tim has ... Inc, with his most recent role as the Director of Manufacturing and Supplier ...
(Date:6/22/2017)... ... 22, 2017 , ... Ovation Fertility supports the American Medical ... new hope for prospective parents who are challenged with costs of treatment. AMA ... Health Organization’s designation in hopes of changing the way health insurers, governments and ...
(Date:6/22/2017)... ... June 22, 2017 , ... The first human cell line HeLa, ... the first data on cross-contamination of human cell lines with HeLa cells were published. ... in cell culture labs and is associated with dramatic consequences for research. , ...
Breaking Biology Technology:
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
(Date:4/4/2017)... --  EyeLock LLC , a leader of iris-based identity ... and Trademark Office (USPTO) has issued U.S. Patent No. ... iris image with a face image acquired in sequence ... th issued patent. "The issuance ... multi-modal biometric capabilities that have recently come to market ...
(Date:3/30/2017)... ANGELES , March 30, 2017  On April ... Hack the Genome hackathon at Microsoft,s ... exciting two-day competition will focus on developing health and ... Hack the Genome is the ... been tremendous. The world,s largest companies in the genomics, ...
Breaking Biology News(10 mins):